Is Editas Medicine Stock a Buy Now?

Is Editas Medicine Stock a Buy Now?

With shares down by 60% in the last three years, Editas Medicine (NASDAQ: EDIT) investors are experiencing a bumpy ride despite the company's impeccable gene-editing credentials. Hitting a home run in clinical trials could be enough to revitalize the buzz around its innovative gene-editing platform. Perhaps the best argument against buying Editas stock is that its drug development pipeline is about to be rendered much less lucrative thanks to a competitor.